Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review

ConclusionRTX is a promising therapeutic tool in CTD-related ILD. This systematic review remarks the unmet need of multicenter prospective studies aiming to evaluate the effectiveness of RTX with adequate sample size and study design.
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research

Related Links:

AbstractInterstitial lung disease (ILD) remains a major cause of morbidity and mortality in systemic sclerosis (SSc). Study aim is to characterize and quantify SSc-ILD by using Computer-Aided Lung Informatics for Pathology Evaluation and Rating (CALIPER). Secondly, our objective is to evaluate which radiological pattern is predictive of lung function decline at 12  months follow-up. In the prospective study (IRB 5435), 66 SSc patients underwent high-resolution computerized tomography (HRCT) at baseline. HRCT was performed according to standard protocol using a CT 64GE light speed VCT power scanner. CALIPER classified ...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
Publication date: Available online 10 January 2020Source: The Lancet Respiratory MedicineAuthor(s): Susan Rahimi
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
In conclusion,IRF5 rs2004640 and rs10488631, andSTAT4 rs7574865 were significantly associated with SSc as a whole. OnlySTAT4 rs7574865 showed a significant difference in allele frequency in SSc-ILD, with the T allele being protective against ILD.Key points•We confirm the associations of the IRF5 SNPs rs2004640 and rs10488631, and the STAT4 SNP rs7574865, with SSc as a whole.•None of the tested SNPs were risk factors for SSc-ILD specifically.•The STAT4 rs7574865 T allele was protective against the development of lung fibrosis in SSc patients.•Further work is required to understand the genetic basis of lu...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
Nintedanib (Ofev) is the first drug approved for the treatment of SSc-ILD, a rare interstitial lung disease associated with systemic sclerosis or scleroderma. This is a new indication for nintedanib, which was previously approved for idiopathic pulmonary fibrosis.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research
ObjectiveTo examine changes in the extent of specific patterns of interstitial lung disease (ILD) as they transition from one pattern to another in response to immunosuppressive therapy in systemic sclerosis –related ILD (SSc‐ILD).MethodsWe evaluated changes in the quantitative extent of specific lung patterns of ILD using volumetric high ‐resolution computed tomography (HRCT) scans obtained at baseline and after 2 years of therapy in patients treated with either cyclophosphamide (CYC) for 1 year or mycophenolate mofetil (MMF) for 2 years in Scleroderma Lung Study II. ILD patterns included lung fibrosis, ground g...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
This study aimed to investigate the role of an inflammatory lipid mediator, leukotriene B4 (LTB4), and its receptor BLT1 in systemic sclerosis (SSc).MethodsSerum levels of LTB4 were compared in 64 subjects with SSc and 80 healthy controls (HC). Skin and lung sections were immunostained with leukotriene A4 hydrolase (LTA4H), the critical enzyme for LTB4 synthesis, and BLT1, in combination with different cell markers. The LTB4‐BLT1 axis was genetically or pharmacologically interrupted in mouse models of SSc induced by bleomycin or angiotensin II, or immunized with the DNA topoisomerase I. Immunoblotting was performed to ex...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: FULL LENGTH Source Type: research
CONCLUSIONS: Anti-alpha enolase antibodies are very frequent in SSc but are not associated with clinical or serological features of the disease. Further studies on larger cohorts of patients are necessary to define their possible contribution in defining specific subsets of the disease. PMID: 31858961 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). PMID: 31841044 [PubMed - as supplied by publisher]
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Am J Respir Crit Care Med Source Type: research
This study was registered at ClinicalTrials.gov (NCT02896205).
Source: Rheumatology International - Category: Rheumatology Source Type: research
ObjectiveTo investigate the relationship between Krebs von den Lungen 6 (KL ‐6) and CCL18 levels and the severity and progression of systemic sclerosis (SSc)–related interstitial lung disease (ILD).MethodsPatients enrolled in the Scleroderma Lung Study II (cyclophosphamide [CYC] versus mycophenolate mofetil [MMF]) were included. Baseline and 12 ‐month plasma samples were analyzed by enzyme‐linked immunosorbent assay to assess CCL18 and KL‐6 levels. The forced vital capacity (FVC) and the diffusing capacity for carbon monoxide (DLco) were measured every 3 months. Joint models were created to investigate the re...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
More News: Allergy & Immunology | Clinical Trials | Interstitial Lung Disease | Rituxan | Scleroderma | Study